Ensysce Biosciences posts $3.7 million net loss for Q3 2025

Reuters

2025/11/15

Ensysce Biosciences posts $3.7 million net loss for Q3 2025

Ensysce Biosciences Inc. reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583319684"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583319684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583319684?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583319684","market":"nz","top_or_hot":-1,"title":"Ensysce Biosciences posts $3.7 million net loss for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences posts $3.7 million net loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a> reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences posts $3.7 million net loss for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences posts $3.7 million net loss for Q3 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-15 05:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ensysce Biosciences posts $3.7 million net loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a> reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL7jdrf5:1","article_id":"2583319684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583319684","pubTimestamp":1763154923,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ensysce Biosciences Inc. reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences公布2025年第三季度净亏损370万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"Ensysce Biosciences posts $3.7 million net loss for Q3 2025\n    \n\nEnsysce Biosciences Inc. reported a net loss attributable to common stockholders of $3.7 million for the third quarter of 2025, compared to a gain of $0.7 million in the same period of 2024. Cash and cash equivalents were $1.7 million as of September 30, 2025, down from $3.5 million at the end of 2024. Other income for the third quarter of 2025 was $12.0 thousand, compared to $17.0 thousand in the third quarter of 2024. Federal grants provided $0.5 million in funding for the quarter, a decrease from $3.4 million in the prior year period. During the quarter, Ensysce initiated its pivotal Phase 3 study of PF614 and completed a convertible preferred stock offering in November 2025, raising $4.0 million with up to $16.0 million in additional funding possible over the next 24 months.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102648) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}